Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women

Pharmacogenetics and Genomics

Volumn 16, Issue 8, 2006, Pages 547-553

  Gaudet, Mia M ^a   Chanock, Stephen ^a   Lissowska, Jolanta ^a,b   Berndt, Sonja I ^a   Yang, Xiaohong ^a   Peplonska, Beata ^c   Brinton, Louise A ^a   Welch, Robert ^a   Yeager, Meredith ^a   Bardin Mikolajczak, Alicja ^b   Sherman, Mark E ^a   Sutter, Thomas R ^d,e   Garcia Closas, Montserrat ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Breast cancer; CYP1B1; Family history; Haplotypes; P450s

Indexed keywords

CYTOCHROME P450 1B1; HORMONE RECEPTOR;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; EVALUATION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLAND; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETICS, POPULATION; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VARIATION (GENETICS);

EID: 33746255666     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000215067.29342.6f     Document Type: Article

References (32)

1. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 1996; 93:9776-9781.
2. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000; 27:67-73.
3. Creveling CR, Kirk KL. The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DORA) by catechol-O-methyltransferase: significance in the development of 18F-PETT scanning agents. Biochem Biophys Res Commun 1985; 130:1123-1131.
4. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000; 60:3440-3444.
5. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999; 20:1607-1613.
6. Wen W, Cai Q, Shu XO, Cheng JR, Pari F, Pierce L, et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14:329-335.
7. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:489-492.
8. Bailey LR, Roodi N, Dupont WD, Pari FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998; 58:5038-5041.
9. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson W, et al. Established breast cancer risk factors by clinically important tumor characteristics. 2006; submitted.
10. The National Cancer Institute Breast and Prostate Cancer Cohort Consortium. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005; 5:977-985.
11. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12:921-927.
12. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003; 55:27-36.
13. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998; 62:573-584.
14. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57:3026-3031.
15. Packer BR, Yeager M, Staats B, Welch R, Crenshaw A, Kiley M, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004; 32:D528-D532.
16. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 2004; 199:210-219.
17. Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 2002; 3:299-309.
18. Zondervan KT, Cardon LR. The complex interplay among factors that influence allelic association. Nat Rev Genet 2004; 5:89-100.
19. Schaid DJ, Rowland CM. Robust transmission regression models for linkage and association. Genet Epidemiol 2000; 19 (Suppl 1):S78-S84.
20. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434.
21. Mammen JS, Pittman GS, Li Y, Abou-Zahr F, Bejjani BA, Bell DA, et al. Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 2003; 24:1247-1255.
22. Han W, Pentecost BT, Spivack SD. Functional evaluation of novel single nucleotide polymorphisms and haplotypes in the promoter regions of CYP1B1 and CYP1A1 genes. Mol Carcinog 2003; 37:158-169.
23. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405:847-856.
24. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005; 227:115-124.
25. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 2004; 64:3119-3125.
26. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004; 4:850-860.
27. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13:1558-1568.
28. Rylander-Rudqvist T, Wedren S, Granath F, Humphreys K, Ahlberg S, Weiderpass E, et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 2003; 24:1533-1539.
29. Modugno F, Knoll C, Kanbour-Shakir A, Romkes M. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast Carcinogenesis. Breast Cancer Res Treat 2003; 82:191-197.
30. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol 2006; 163:197-203.
31. Pharoah PD, Dunning AM, Ponder BA, Easton DF. The reliable identification of disease-gene associations. Cancer Epidemiol Biomarkers Prev 2005; 14:1362.
32. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001; 69:124-137.